WGU D116 ADVANCED PHARMACOLOGY FINAL EXAM
OBJECTIVE ASSESSMENT & PRE-ASSESSMENT |
COMPLETE PRACTICE QUESTION BANK WITH
VERIFIED ANSWERS AND DETAILED RATIONALES
Core Domains
• Pharmacokinetics and Pharmacodynamics
• Cardiovascular and Renal Pharmacology
• Respiratory and Allergy Pharmacology
• Endocrine and Metabolic Pharmacology
• Neurologic and Psychiatric Pharmacology
• Infectious Disease and Antimicrobials
• Special Populations, Toxicology, and Clinical Application
Introduction
This comprehensive examination assesses advanced
pharmacology knowledge essential for the advanced practice
registered nurse. It evaluates pharmacokinetic principles
including absorption, distribution, metabolism, and excretion, as
well as pharmacodynamic mechanisms of drug action.
Questions emphasize drug classifications, mechanisms of action,
adverse effects, drug interactions, and evidence-based
prescribing practices. The examination integrates clinical
decision-making, patient safety, and regulatory considerations
to prepare learners for the WGU D116 Objective Assessment.
Successful completion demonstrates competency in safe and
,effective pharmacologic management across diverse patient
populations and disease states.
1. Which of the following best describes the difference
between pharmacokinetics and pharmacodynamics?
A. Pharmacokinetics is what the drug does to the body;
pharmacodynamics is what the body does to the drug
B. Pharmacokinetics is what the body does to the drug;
pharmacodynamics is what the drug does to the body
C. There is no meaningful difference between pharmacokinetics
and pharmacodynamics
D. Pharmacokinetics involves drug efficacy; pharmacodynamics
involves drug metabolism
Correct answer: B. Pharmacokinetics is what the body does
to the drug; pharmacodynamics is what the drug does to the
body
RATIONALE: Pharmacokinetics describes "what the body
does to the drug" and encompasses absorption, distribution,
metabolism, and excretion (ADME). Pharmacodynamics
describes "what the drug does to the body"—the biochemical
and physiological effects of drugs and their mechanisms of
action .
2. A patient with liver cirrhosis is prescribed propranolol.
The APRN understands that the oral bioavailability of this
,drug will be significantly increased due to which
pharmacokinetic phenomenon?
A. Increased volume of distribution
B. Decreased first-pass metabolism
C. Enhanced renal tubular secretion
D. Increased plasma protein binding
Correct answer: B. Decreased first-pass metabolism
RATIONALE: Propranolol undergoes extensive first-pass
hepatic metabolism. In cirrhosis, reduced hepatic blood flow and
decreased enzyme activity reduce first-pass extraction, thereby
increasing oral bioavailability .
3. The "first-pass effect" refers to:
A. Rapid intravenous administration of a medication
B. Drug metabolism in the liver before reaching systemic
circulation
C. Drug excretion by the kidneys before distribution
D. Drug binding to plasma proteins after absorption
Correct answer: B. Drug metabolism in the liver before
reaching systemic circulation
RATIONALE: The first-pass effect occurs when orally
administered drugs are metabolized in the liver before reaching
systemic circulation, reducing bioavailability. Drugs such as
, nitroglycerin and morphine require higher oral doses or
alternative routes to bypass this effect .
4. Bioavailability is defined as:
A. The speed at which a drug is absorbed
B. The fraction of an administered dose that reaches systemic
circulation unchanged
C. The volume of distribution of a drug
D. The half-life of a drug
Correct answer: B. The fraction of an administered dose that
reaches systemic circulation unchanged
RATIONALE: Bioavailability measures the proportion of
an administered drug dose that reaches the systemic circulation
in unchanged form. Intravenous administration has 100%
bioavailability because it bypasses absorption and first-pass
metabolism .
5. Which route of administration has the highest
bioavailability and fastest onset of action?
A. Oral
B. Subcutaneous
C. Intravenous (IV)
D. Intramuscular (IM)
OBJECTIVE ASSESSMENT & PRE-ASSESSMENT |
COMPLETE PRACTICE QUESTION BANK WITH
VERIFIED ANSWERS AND DETAILED RATIONALES
Core Domains
• Pharmacokinetics and Pharmacodynamics
• Cardiovascular and Renal Pharmacology
• Respiratory and Allergy Pharmacology
• Endocrine and Metabolic Pharmacology
• Neurologic and Psychiatric Pharmacology
• Infectious Disease and Antimicrobials
• Special Populations, Toxicology, and Clinical Application
Introduction
This comprehensive examination assesses advanced
pharmacology knowledge essential for the advanced practice
registered nurse. It evaluates pharmacokinetic principles
including absorption, distribution, metabolism, and excretion, as
well as pharmacodynamic mechanisms of drug action.
Questions emphasize drug classifications, mechanisms of action,
adverse effects, drug interactions, and evidence-based
prescribing practices. The examination integrates clinical
decision-making, patient safety, and regulatory considerations
to prepare learners for the WGU D116 Objective Assessment.
Successful completion demonstrates competency in safe and
,effective pharmacologic management across diverse patient
populations and disease states.
1. Which of the following best describes the difference
between pharmacokinetics and pharmacodynamics?
A. Pharmacokinetics is what the drug does to the body;
pharmacodynamics is what the body does to the drug
B. Pharmacokinetics is what the body does to the drug;
pharmacodynamics is what the drug does to the body
C. There is no meaningful difference between pharmacokinetics
and pharmacodynamics
D. Pharmacokinetics involves drug efficacy; pharmacodynamics
involves drug metabolism
Correct answer: B. Pharmacokinetics is what the body does
to the drug; pharmacodynamics is what the drug does to the
body
RATIONALE: Pharmacokinetics describes "what the body
does to the drug" and encompasses absorption, distribution,
metabolism, and excretion (ADME). Pharmacodynamics
describes "what the drug does to the body"—the biochemical
and physiological effects of drugs and their mechanisms of
action .
2. A patient with liver cirrhosis is prescribed propranolol.
The APRN understands that the oral bioavailability of this
,drug will be significantly increased due to which
pharmacokinetic phenomenon?
A. Increased volume of distribution
B. Decreased first-pass metabolism
C. Enhanced renal tubular secretion
D. Increased plasma protein binding
Correct answer: B. Decreased first-pass metabolism
RATIONALE: Propranolol undergoes extensive first-pass
hepatic metabolism. In cirrhosis, reduced hepatic blood flow and
decreased enzyme activity reduce first-pass extraction, thereby
increasing oral bioavailability .
3. The "first-pass effect" refers to:
A. Rapid intravenous administration of a medication
B. Drug metabolism in the liver before reaching systemic
circulation
C. Drug excretion by the kidneys before distribution
D. Drug binding to plasma proteins after absorption
Correct answer: B. Drug metabolism in the liver before
reaching systemic circulation
RATIONALE: The first-pass effect occurs when orally
administered drugs are metabolized in the liver before reaching
systemic circulation, reducing bioavailability. Drugs such as
, nitroglycerin and morphine require higher oral doses or
alternative routes to bypass this effect .
4. Bioavailability is defined as:
A. The speed at which a drug is absorbed
B. The fraction of an administered dose that reaches systemic
circulation unchanged
C. The volume of distribution of a drug
D. The half-life of a drug
Correct answer: B. The fraction of an administered dose that
reaches systemic circulation unchanged
RATIONALE: Bioavailability measures the proportion of
an administered drug dose that reaches the systemic circulation
in unchanged form. Intravenous administration has 100%
bioavailability because it bypasses absorption and first-pass
metabolism .
5. Which route of administration has the highest
bioavailability and fastest onset of action?
A. Oral
B. Subcutaneous
C. Intravenous (IV)
D. Intramuscular (IM)
